Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
that made its COVID-19 vaccine possible, removing an overhang and ?allowing it to focus on its pipeline. Analysts noted the settlement, which involves paying up to $2.25 billion ?to a Roivant Sciences' Genevant subsidiary, and Arbutus Biopharma, would shift investor focus back to Moderna's cancer vaccines that are under development. This resolves all U.S. and international legal actions accusing Moderna of unauthorized use of lipid nanoparticle (LNP) technology owned ?by Genevant and Arbutus in ?its COVID vaccine. "The company (now) has certainty it is well funded through multiple late-stage oncology readouts expected in 2026 that represent ?new long-term growth drivers," said William Blair analyst Myles Minter. Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion contingent on the outcome of ?a separate ?legal appeal, while not owing royalties for ?the technology in its future ?vaccines, which is seen as a significant win for the company. The pa
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (ROIV) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance Canada]Yahoo! Finance Canada
- Roivant Sciences (ROIV) had its price target raised by HC Wainwright from $33.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders [Yahoo! Finance]Yahoo! Finance
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 3/3/26 - Form 8-K
- 3/3/26 - Form 8-K
- 2/24/26 - Form 4
- ROIV's page on the SEC website